Literature DB >> 2862692

In vitro effects of sulphasalazine, azodisal sodium, and their metabolites on Clostridium difficile and some other faecal bacteria.

H Sandberg-Gertzen, J Kjellander, B Sundberg-Gillå, G Järnerot.   

Abstract

The effects of sulphasalazine (SASP), azodisal sodium (ADS), and their metabolites were tested in vitro on aerobic and anaerobic faecal bacterial strains. Sulphapyridine (SP) had a mild to moderate effect on Escherichia coli and Streptococcus faecalis. SASP also had a growth-inhibitory effect on Strep. faecalis. The other substances had no effect on the aerobic strains. SASP, SP, 5-aminosalicylic acid, and, to a certain extent, N-acetyl-5-aminosalicylic acid exerted a growth-inhibitory effect on the anaerobic strains. Of special interest was the inhibitory effect on Clostridium difficile strains. In recent years the possibility that overgrowth of Cl. difficile could cause flare-ups of inflammatory bowel disease has been discussed. Some studies suggested that SASP treatment could predispose to Cl. difficile superinfection, whereas others found SASP more probable to exert a prophylactic effect. Our findings support the theory that SASP treatment reduces rather than promotes the risk of Cl. difficile superinfection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2862692     DOI: 10.3109/00365528509089704

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  5 in total

1.  Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid.

Authors:  C Deloménie; S Fouix; S Longuemaux; N Brahimi; C Bizet; B Picard; E Denamur; J M Dupret
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

Review 2.  Drug-gut microbiota interactions: implications for neuropharmacology.

Authors:  Jacinta Walsh; Brendan T Griffin; Gerard Clarke; Niall P Hyland
Journal:  Br J Pharmacol       Date:  2018-06-28       Impact factor: 8.739

Review 3.  Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.

Authors:  A N Wadworth; A Fitton
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

4.  Clostridium difficile, sulphasalazine, and ulcerative colitis.

Authors:  D A Burke; A T Axon
Journal:  Postgrad Med J       Date:  1987-11       Impact factor: 2.401

5.  Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.

Authors:  Maya Olaisen; Olav Spigset; Arnar Flatberg; Atle van Beelen Granlund; Wenche Rødseth Brede; Grethe Albrektsen; Elin Synnøve Røyset; Bodil Gilde; Arne Kristian Sandvik; Tom Christian Martinsen; Reidar Fossmark
Journal:  Aliment Pharmacol Ther       Date:  2019-03-20       Impact factor: 8.171

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.